Our Funding
Overview
Our funders
SMA Europe receives funding from its member organisations, in the form of an annual membership fee and of voluntary donations towards our Call for Research Proposals. In addition, we receive funding from other non-profit organisations and from health sector corporates.
Our funders respect SMA Europe’s mission, strategy, independence, and integrity.
SMA Europe has adopted a code of practice for relationships with the pharmaceutical industry and all our funding partnerships are established with shared interest, transparency, trust, and mutual benefit.
For more information, please contact us at secretariat@sma-europe.eu.
Breakdown
Financial information 2023
In 2023 SMA Europe’s annual revenue was €1,232,280.13, while the organisation’s total annual expenses amounted to €1,187,013.98.
Valued support
Acknowledgements
SMA Europe appreciates the contributions received from all its funders as well as all support from its partners and various collaborators.
SMA Europe would like to thank the following organisations for their highly valued support in 2023:
SMA Europe Member Organisations
SMA Europe Partner Organisations
- Cure SMA (US)
- Cure SMA India
- EAMDA
- European Medicines Agency (EMA)
- ENMC
- EURO-NMD
- Eurordis
- SMA Foundation (US)
- Treat-NMD
SMA Europe Industry Partners
- Asuragen (Bio-Techne)
- Biohaven
- Biogen
- ImmunoIVD
- LaCAR MDX Technologies
- Novartis Gene Therapies
- Roche
- Scholar Rock
Related resources